Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 38 results.
User Information
Export Records
  1. 1.   Mechanistic Differences of Activation of Rac1(P29S) and Rac1(A159V)
  2. Senyuz, Simge; Jang,Hyunbum; Nussinov,Ruth; Keskin, Ozlem; Gursoy, Attila
  3. Journal of Physical Chemistry B. 2021, Apr 22; 125(15): 3790-3802.
  1. 2.   Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-Schlafen 11and low-MGMT expression
  2. Rathkey, Daniel; Khanal, Manakamana; Murai, Junko; Zhang, Jingli; Sengupta, Manjistha; Jiang, Qun; Morrow, Betsy; Evans,Christine; Chari,Raj; Fetsch, Patricia; Chung, Hye-Jung; Xi, Liqiang; Roth, Mark; Filie, Armando; Raffeld, Mark; Thomas, Anish; Pommier, Yves; Hassan, Raffit
  3. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2020, Jan 28; pii: S1556-0864(20)30035-6.
  1. 3.   Plasma and CNS pharmacokinetics of O(4)-benzylfolic acid (O(4)BF) and metabolite in a non-human primate model
  2. Chuk, M. K.; Cole, D. E.; McCully, C.; Loktionova, N. A.; Pegg, A. E.; Parker, R. J.; Pauly, G.; Widemann, B. C.; Balis, F. M.; Fox, E.
  3. Cancer Chemotherapy and Pharmacology. 2011, Jun; 67(6): 1291-1297.
  1. 4.   In vitro comparison of O4-benzylfolate modulated, BCNU-induced toxicity in human bone marrow using CFU-GM and tumor cell lines
  2. Behrsing, H. P.; Furniss, M. J.; Robillard, K. A.; Tomaszewski, J. E.; Parchment, R. E.
  3. Cancer Chemotherapy and Pharmacology. 2010, May; 65(6): 1083-1091.
  1. 5.   Substitution of Aminomethyl at the Meta-Position Enhances the Inactivation of O-6-Alkylguanine-DNA Alkyltransferase by O-6-Benzylguanine
  2. Pauly, G. T.; Loktionova, N. A.; Fang, Q. M.; Vankayala, S. L.; Guida, W. C.; Pegg, A. E.
  3. Journal of Medicinal Chemistry. 2008 51(22): 7144-7153.
  1. 6.   Degradation of BRCA2 in Alkyltransferase-Mediated DNA Repair and Its Clinical Implications
  2. Philip, S.; Swaminathan, S.; Kuznetsov, S. G.; Kanugula, S.; Biswas, K.; Chang, S.; Loktionova, N. A.; Haines, D. C.; Kaldis, P.; Pegg, A. E.; Sharant, S. K.
  3. Cancer Research. 2008 68(23): 9973-9981.
  1. 7.   Polymorphisms in DNA repair genes and risk of non-Hodgkin's lymphoma in New South Wales, Australia
  2. Shen, M.; Purdue, M. R.; Kricker, A.; Lan, Q.; Grulich, A. E.; Vajdic, C. M.; Turner, J.; Whitby, D.; Chanock, S.; Rothman, N.; Armstrong, B. K.
  3. Haematologica-the Hematology Journal. 2007, Sep; 92(9): 1180-1185.
  1. 8.   Phase I trial of temozolomide plus O-6-benzylguanine for patients with recurrent or progressive malignant glioma
  2. Quinn, J. A.; Desjardins, A.; Weingart, J.; Brem, H.; Dolan, M. E.; Delaney, S. M.; Vredenburgh, J.; Rich, J.; Friedman, A. H.; Reardon, D. A.; Sampson, J. H.; Pegg, A. E.; Moschel, R. C.; Birch, R.; McLendon, R. E.; Provenzale, J. M.; Gururangan, S.; Dancey, J. E.; Maxwell, J.; Tourt-Uhlig, S.; Herndon, J. E.; Bigner, D. D.; Friedman, H. S.
  3. Journal of Clinical Oncology. 2005, OCT 1; 23(28): 7178-7187.
  1. 9.   A bifunctional DNA repair protein from Ferroplasma acidarmanus exhibits O-6-alkylguanine-DNA alkyltransferase and endonuclease V activities
  2. Kanugula, S.; Pauly, G. T.; Moschel, R. C.; Pegg, A. E.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2005, MAR 8; 102(10): 3617-3622.
  1. 10.   Effect of cell cycle inhibition on cisplatin-induced cytotoxicity
  2. Fishel, M. L.; Newell, D. R.; Griffin, R. J.; Davison, R.; Wang, L. Z.; Curtin, N. J.; Zuhowski, E. G.; Kasza, K.; Egorin, M. J.; Moschel, R. C.; Dolan, M. E.
  3. Journal of Pharmacology and Experimental Therapeutics. 2005, JAN; 312(1): 206-213.
  1. 11.   Intra- and intercellular variations in the repair efficiency of O-6-methylguanine, and their contribution to kinetic complexity
  2. Souliotis, V. L.; Sfikakis, P. P.; Anderson, L. M.; Kyrtopoulos, S. A.
  3. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis. 2004, DEC 21; 568(2): 155-170.
  1. 12.   Brain tumor cell lines resistant to O-6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O-6 -alkylguanine-DNA alkyltransferase mutations
  2. Bacolod, M. D.; Johnson, S. P.; Pegg, A. E.; Dolan, M. E.; Moschel, R. C.; Bullock, N. S.; Fang, Q. M.; Colvin, O. M.; Modrich, P.; Bigner, D. D.; Friedman, H. S.
  3. Molecular Cancer Therapeutics. 2004, SEP; 3(9): 1127-1135.
  1. 13.   2-amino-O-4-benzylpteridines and O-4-benzylfolic acid: Potent inactivators of O-6-alkylguanine-DNA alkyltransferase and potential chemotherapy adjuvants
  2. Nelson, M. E.; Loktionova, N.; Pegg, A. E.; Moschel, R. C.
  3. Abstracts of Papers of the American Chemical Society. 2004, AUG 22; 228(Part 1): 110-MEDI, Abstract U927-110-MEDI, Abstract U927.
  1. 14.   Profiling the activity of G proteins in patient-derived tissues by rapid affinity-capture of signal transduction proteins (GRASP)
  2. Berman, D. M.; Shih, L. M.; Burke, L. A.; Veenstra, T. D.; Zhao, Y. M.; Conrads, T. P.; Kwon, S. W.; Hoang, V.; Yu, L. R.; Zhou, M.; Kurman, R. J.; Petricoin, E. F.; Liotta, L. A.
  3. Proteomics. 2004 4(3): 812-818.
  1. 15.   The repair of the tobacco specific nitrosamine derived adduct O-6-[4-oxo-4-(3-pyridyl)butyl]guanine by O-6-alkylguanine-DNA alkyltransferase variants
  2. Mijal, R. S.; Thomson, N. M.; Fleischer, N. L.; Pauly, G. T.; Moschel, R. C.; Kanugula, S.; Fang, Q. M.; Pegg, A. E.; Peterson, L. A.
  3. Chemical Research in Toxicology. 2004 17(3): 424-434.
  1. 16.   Enhancement of platinum-induced cytotoxicity by O-6- Benzylguanine
  2. Fishel, M. L.; Delaney, S. M.; Friesen, L. D.; Hansen, R. J.; Zuhowski, E. G.; Moschel, R. C.; Egorin, M. J.; Dolan, M. E.
  3. Molecular Cancer Therapeutics. 2003 2(7): 633-640.
  1. 17.   Repair of oligodeoxyribonucleotides by O-6-alkylguanine-DNA alkyltransferase
  2. Luu, K. X.; Kanugula, S.; Pegg, A. E.; Pauly, G. T.; Moschel, R. C.
  3. Biochemistry. 2002 41(27): 8689-8697.
  1. 18.   O-6-benzylguanine-mediated enhancement of chemotherapy
  2. Friedman, H. S.; Keir, S.; Pegg, A. E.; Houghton, P. J.; Colvin, O. M.; Moschel, R. C.; Bigner, D. D.; Dolan, M. E.
  3. Molecular Cancer Therapeutics. 2002 1(11): 943-948.
  1. 19.   Mutagenesis by O-6- 4-oxo-4-(3-pyridyl)butyl guanine in Escherichia coli and human cells
  2. Pauly, G. T.; Peterson, L. A.; Moschel, R. C.
  3. Chemical Research in Toxicology. 2002 15(2): 165-169.
  1. 20.   Phase II trial of carmustine plus O-6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma
  2. Quinn, J. A.; Pluda, J.; Dolan, M. E.; Delaney, S.; Kaplan, R.; Rich, J. N.; Friedman, A. H.; Reardon, D. A.; Sampson, J. H.; Colvin, O. M.; Haglund, M. M.; Pegg, A. E.; Moschel, R. C.; McLendon, R. E.; Provenzale, J. M.; Gururangan, S.; Tourt-Uhlig, S.; Herndon, J. E.; Bigner, D. D.; Friedman, H. S.
  3. Journal of Clinical Oncology. 2002 20(9): 2277-2283.
  1. 21.   DNA adducts and liver DNA replication in rats during chronic exposure to N-nitrosodimethylamine (NDMA) and their relationships to the dose-dependence of NDMA hepatocarcinogenesis
  2. Souliotis, V. L.; Henneman, J. R.; Reed, C. D.; Chhabra, S. K.; Diwan, B. A.; Anderson, L. M.; Kyrtopoulos, S. A.
  3. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis. 2002 500(1-2): 75-87.
  1. 22.   Interactions of antimitotic peptides and depsipeptides with tubulin
  2. Hamel, E.
  3. Biopolymers. 2002 66(3): 142-160.
  1. 23.   Debenzylation of O-6-benzyl-8-oxoguanine in human liver: implications for O-6-benzylguanine metabolism
  2. Long, L.; Moschel, R. C.; Dolan, M. E.
  3. Biochemical Pharmacology. 2001 61(6): 721-726.
  1. 24.   Thresholds of O-6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide
  2. Kokkinakis, D. M.; Bocangel, D. B.; Schold, S. C.; Moschel, R. C.; Pegg, A. E.
  3. Clinical Cancer Research. 2001 7(2): 421-428.
  1. 25.   Phase I trial of carmustine plus O-6-benzylguanine for patients with recurrent or progressive malignant glioma
  2. Friedman, H. S.; Pluda, J.; Quinn, J. A.; Ewesuedo, R. B.; Long, L.; Friedman, A. H.; Cokgor, I.; Colvin, O. M.; Haglund, M. M.; Ashley, D. M.; Rich, J. N.; Sampson, J.; Pegg, A. E.; Moschel, R. C.; McLendon, R. E.; Provenzale, J. M.; Stewart, E. S.; Tourt-Uhlig, S.; Garcia-Turner, A. M.; Herndon, J. E.; Bigner, D. D.; Dolan, M. E.
  3. Journal of Clinical Oncology. 2000 18(20): 3522-3528.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel